: Diagram for the inclusion of anticancer agents that were analyzed. All FDA-approved cancer-related agents were screened between January 1, 1998, and March 14, 2015. All non-chemotherapeutic agents, duplicate agents, and cytotoxic agents were excluded. FDA labels were retrieved for the remaining agents, and all agents that displayed evidence of ocular adverse events were included in the study. A total of 16 agents (4 monoclonal antibodies and 12 small-molecule targeted inhibitors) were initially included in the study. Four agents (bortezomib, pertuzumab, dabrafenib, and idelalisib) were associated with minor ocular adverse events according to the FDA label, but no evidence of ocular toxicity was evident upon an independent survey of the literature; these agents were therefore excluded.
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